These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3129986)

  • 1. Differences in resistance to reinfection with low and high inocula of Trypanosoma cruzi in chagasic mice treated with nifurtimox and relation to immune response.
    Cabeza Meckert P; Chambó JG; Laguens RP
    Antimicrob Agents Chemother; 1988 Feb; 32(2):241-5. PubMed ID: 3129986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of antibody dependent cytotoxicity to Trypanosoma cruzi in chronic chagasic mice after treatment with nifurtimox.
    Chambó JG; Cabeza Meckert PM; Laguens RP
    Medicina (B Aires); 1988; 48(1):49-53. PubMed ID: 3146009
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of length of treatment with Bayer 2502 on isolation of Trypanosoma cruzi and resistance to challenge in the mouse.
    Morrow DT; Wescott RB; Davis WC
    Am J Trop Med Hyg; 1977 May; 26(3):382-6. PubMed ID: 405877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-mediated immunity in Chagas' disease: Alterations induced by treatment with a trypanocidal drug (nifurtimox).
    Lelchuk R; Cardoni RL; Fuks AS
    Clin Exp Immunol; 1977 Dec; 30(3):434-8. PubMed ID: 414867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the efficacy of nifurtimox in chronic human chagasic infection by using xenodiagnosis (author's transl)].
    Cerisola JA; Neves da Silva N; Prata A; Schenone H; Rohwedder R
    Bol Chil Parasitol; 1977; 32(3-4):51-62. PubMed ID: 416834
    [No Abstract]   [Full Text] [Related]  

  • 6. [Etiological treatment of Chagas' disease].
    Rassi A
    Arq Bras Cardiol; 1982 Apr; 38(4):277-81. PubMed ID: 6820273
    [No Abstract]   [Full Text] [Related]  

  • 7. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
    Faúndez M; López-Muñoz R; Torres G; Morello A; Ferreira J; Kemmerling U; Orellana M; Maya JD
    Antimicrob Agents Chemother; 2008 May; 52(5):1837-9. PubMed ID: 18332173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Etiologic therapy of Chagas' disease].
    Boainain E; Rassi A
    Arq Bras Cardiol; 1979 Jun; 32(6):395-9. PubMed ID: 116629
    [No Abstract]   [Full Text] [Related]  

  • 10. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
    Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H
    Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Isoenzymatic pattern of Trypanosoma cruzi Y strain after specific chemotherapy].
    Silva RC; Santiago CM; Pontes AL; Andrade SG
    Mem Inst Oswaldo Cruz; 1989; 84(1):81-6. PubMed ID: 2108307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
    Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
    Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study.
    Galvao LM; Nunes RM; Cançado JR; Brener Z; Krettli AU
    Trans R Soc Trop Med Hyg; 1993; 87(2):220-3. PubMed ID: 8337734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trypanosoma cruzi: nifurtimox's effect on infectivity.
    Cardoni RL; Rimoldi MT; de Bracco MM
    Exp Parasitol; 1977 Dec; 43(2):370-5. PubMed ID: 413732
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 16. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of anti-B13 antibodies over time in a cohort of chronic infected by Trypanosoma cruzi. Its relationship with specific treatment and clinical status.
    Olivera V; Bizai ML; Arias E; Suasnabar S; Bottasso O; Marcipar I; Fabbro D
    Acta Trop; 2021 Jun; 218():105908. PubMed ID: 33789152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens].
    Moretti E; Cervetta L; Basso B; Castro I; Santamarina N
    Bol Chil Parasitol; 1998; 53(1-2):3-9. PubMed ID: 9830716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of astaxanthin in mice acutely infected with Trypanosoma cruzi.
    Contreras-Ortiz JME; Barbabosa-Pliego A; Oros-Pantoja R; Aparicio-Burgos JE; Zepeda-Escobar JA; Hassan-Moustafa WH; Ochoa-García L; Uxúa Alonso-Fresan M; Tenorio Borroto E; Vázquez-Chagoyán JC
    Parasite; 2017; 24():17. PubMed ID: 28560955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of the pattern of infection and evolution of cardiopathy in experimental Chagas' disease after treatment with immunosuppressive and trypanocidal drugs.
    Cabeza Meckert PM; Chambó JG; Laguens RP
    Medicina (B Aires); 1988; 48(1):7-11. PubMed ID: 3063916
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.